Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140003/S135

Impella 2.5 System; Impella CP System; Impella CP with Smart Assist System; Impella 5.0 System, Impella 5.5 with Smart A

Abiomed, Inc. · Decision date Feb 6, 2026

FDA DECISIONP140003/S135

What did the FDA approve?

FDA records P140003/S135 as a supplement to PMA P140003, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Feb 6, 2026.

FDA approval order statement

approval for a modification to the Instructions for Use to allow sodium bicarbonate to be used in the purge fluid for the Impella catheters if heparin should not be used per the physicians clinical judgement.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Feb 6, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P140003/S135
Regulatory pathway
PMA supplement
Applicant
Abiomed, Inc.
Product code
OZD
Decision code
APPR
Decision date
Feb 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Temporary non-roller type left heart support blood pump.

Applicant
Abiomed, Inc.
Product code
OZD
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P140003/S128 · Related supplement

    Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0, Impella 5.5 with SmartAssist, and Impella LD

  2. P140003/S123 · Related supplement

    Impella 5.5 with SmartAssist System; Impella CP with SmartAssist System; Impella 2.5; Impella 5.0; Impella LD;

  3. P140003/S124 · Related supplement

    Impella CP with SmartAssist System

  4. P140003/S126 · Related supplement

    Impella 5.5 with SmartAssist, Impella CP with SmartAssist, Purge Cassette

  5. P140003/S129 · Related supplement

    Impella 2.5; Impella CP; Impella CP with SmartAssist; Impella 5.0; Impella 5.5 with SmartAssist; Impella LD

  6. P140003/S130 · Related supplement

    Impella CP with SmartAssist

  7. P140003/S131 · Related supplement

    Impella 5.5 with SmartAssist

  8. P140003/S135 received

    Application receipt date recorded by FDA.

  9. P140003/S136 · Related supplement

    Impella CP with SmartAssist; Impella 5.5 with SmartAssist

  10. P140003/S135 · FDA decision

    Real-Time Process

  11. P140003/S137 · Related supplement

    Impella 5.5 with Smart Assist

  12. P140003/S138 · Related supplement

    Impella CP with SmartAssist

Timeline entries are records held by MedtechLedger for P140003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140003

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abiomed, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
22 Cherry Hill Dr., Danvers, MA, 01923

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records